Suppr超能文献

2012-2014 年有医疗保险的新进入血液透析患者动静脉通路的临床结局。

Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.

机构信息

EpidStat Institute, Ann Arbor, Michigan, USA.

Humacyte Incorporated, Morrisville, North Carolina, USA.

出版信息

Am J Nephrol. 2019;49(2):156-164. doi: 10.1159/000495355. Epub 2019 Jan 24.

Abstract

BACKGROUND

Chronic hemodialysis requires a mode of vascular access through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter (CVC). AVF is recommended over AVG or CVC due to increased patency and decreased intervention rates for those that mature. AVG are preferred over CVC due to decreased infection and mortality risk. The aims of this study were to evaluate the lifespan of AVF and AVG in maturation, sustained access use, and abandonment.

METHODS

The United States Renal Data System (USRDS), Medicare claims, and CROWNWeb were used to identify access placements. Patients with a first end-stage renal disease (ESRD) service from January 1, 2012 to June 30, 2014 with continuous coverage with Medicare as primary payer and ≥1 AVF or AVG placed after ESRD onset were included. Maturation was defined as the first use of the access for hemodialysis recorded in CROWNWeb. Sustained access use was defined as 3 consecutive months of use without catheter placement or replacement. Accesses that were never used at any time post-placement were considered abandoned.

RESULTS

The cohort included 38,035 AVF placements and 12,789 AVG placements. Sixty-nine percent of AVF and 72% of AVG matured. Fifty-two percent of AVF and 51% of AVG achieved sustained access use. One quarter of AVF and 14% of AVG were abandoned without use as recorded in CROWNWeb.

CONCLUSION

Although considered the gold standard for vascular access, only half of AVF and AVG placements achieved sustained access use. The USRDS database has inherent limitations but provides useful clinical insight into maturation, sustained use, and abandonment.

摘要

背景

慢性血液透析需要通过动静脉瘘(AVF)、人工动静脉移植物(AVG)或中心静脉导管(CVC)建立血管通路。由于成熟后通畅率增加和干预率降低,AVF 优于 AVG 或 CVC。由于感染和死亡率降低,AVG 优于 CVC。本研究的目的是评估 AVF 和 AVG 在成熟、持续使用和废弃方面的寿命。

方法

使用美国肾脏数据系统(USRDS)、医疗保险索赔和 CROWNWeb 来确定通路的放置。纳入标准为 2012 年 1 月 1 日至 2014 年 6 月 30 日首次接受终末期肾病(ESRD)服务、持续以医疗保险为主要支付者、在 ESRD 发病后至少放置过 1 个 AVF 或 AVG 的患者。成熟定义为 CROWNWeb 中记录的第一次用于血液透析的通路使用。持续通路使用定义为连续 3 个月无导管放置或更换。任何时候都未使用过的通路被认为是废弃的。

结果

该队列包括 38035 个 AVF 放置和 12789 个 AVG 放置。69%的 AVF 和 72%的 AVG 成熟。52%的 AVF 和 51%的 AVG 实现了持续通路使用。四分之一的 AVF 和 14%的 AVG 未使用(如 CROWNWeb 中记录)而被废弃。

结论

尽管 AVF 被认为是血管通路的金标准,但只有一半的 AVF 和 AVG 放置实现了持续通路使用。USRDS 数据库存在固有局限性,但为成熟、持续使用和废弃提供了有用的临床见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验